Wiley Bros. Aintree Capital, LLC Halozyme Therapeutics, Inc. Transaction History
Wiley Bros. Aintree Capital, LLC
- $5.07 Billion
- Q3 2024
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 3,715 shares of HALO stock, worth $177,539. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,715Holding current value
$177,539% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding HALO
# of Institutions
544Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$842 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$616 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$317 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$194 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$163 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $6.66B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...